Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


340B Audit ‘Protections’ Needed Prior To Dispute Resolution Final Rule, Lilly Tells OMB

Executive Summary

Lilly wants White House Office of Management and Budget to delay final rule until there are regulatory controls against duplicate and diverted discounts. OMB has also held three meetings over past few months with organizations representing 340B providers.

You may also be interested in...

340B Program At ‘Critical Inflection Point,’ Oversight Agency Head Tells Providers

The head of the federal agency overseeing the 340B drug discount program offers unusually direct calls for legislative action during the safety net provider association winter conference. But is action likely in Congress any time soon?

Senate 340B Draft Bill May Add Contract Pharmacy Limits, Has Placeholder For Patient Definition

A bipartisan group of senators issues a request for information to fill gaps in their wide-ranging draft bill on the 340B program. The legislation covers the participation of contract pharmacies, eligibility of "child sites," claims transparency, abuses by pharmacy benefit managers, and a third party claims clearinghouse that would monitor for duplicate discounts.

340B Court Decision Threatens To Expand Patient Eligibility; Can Pharmacy Restrictions Counter Program Growth?

Court ruling in litigation brought against the US government by Genesis Healthcare may elicit competing reactions among stakeholders but is expected to stir up the 340B market.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts